Biotech Values

[DewDiligence]

Re: All-oral HCV combination study

Roche had been promising the start of an all-oral HCV trial in the near future (#msg-32650999).

(I cited such a development in a recent thread questioning the underlying rationale of ZGEN’s IFN-lambda program (#msg-32638280).)

Until recently, the only question was whether Roche would pair ITMN181 with R7128 or with R1626, Roche’s in-house polymerase inhibitor. With the recently announced demise of R1626 due to toxicity (#msg-33022867), the decision to go forward with R7128 became automatic.

The ITMN-191 + R7128 trial will be watched like a hawk by every player in the HCV arena. I would not be surprised to see other all-oral combinations enter phase-1 even before the outcome of the Roche trial is known.